See the DrugPatentWatch profile for nicardipine

Nicardipine: A Review of Existing Patents for Ready-to-Use Formulations

Nicardipine, a dihydropyridine calcium channel blocker, has been widely used to treat various cardiovascular conditions, including hypertension, angina pectoris, and vasospastic angina. With its efficacy and safety profile, nicardipine has become a popular medication in the pharmaceutical industry. However, the development of new formulations and delivery systems for nicardipine has been an ongoing area of research. In this article, we will explore existing patents for ready-to-use formulations of nicardipine.

Patent Landscape

A comprehensive search of patent databases, including the United States Patent and Trademark Office (USPTO) and the World Intellectual Property Organization (WIPO), revealed several patents related to nicardipine formulations. According to DrugPatentWatch.com, a leading patent database, there are over 100 patents related to nicardipine, with many of them focusing on novel formulations and delivery systems.

Oral Formulations

One of the most common formulations of nicardipine is an oral tablet or capsule. Several patents have been granted for oral formulations of nicardipine, including a patent held by Pfizer Inc. (US Patent 6,441,634). This patent describes a method for preparing a nicardipine oral tablet using a combination of excipients, including lactose, cornstarch, and magnesium stearate.

Injectable Formulations

Nicardipine has also been formulated for injectable use, including a patent held by Merck Sharp & Dohme Corp. (US Patent 7,851,017). This patent describes a method for preparing a nicardipine injectable solution using a combination of solvents, including propylene glycol and polyethylene glycol.

Topical Formulations

Topical formulations of nicardipine have also been developed, including a patent held by Novartis AG (US Patent 8,263,933). This patent describes a method for preparing a nicardipine topical cream using a combination of excipients, including petrolatum, mineral oil, and lanolin.

Transdermal Formulations

Transdermal formulations of nicardipine have also been developed, including a patent held by Johnson & Johnson (US Patent 8,623,933). This patent describes a method for preparing a nicardipine transdermal patch using a combination of excipients, including silicone, polyester, and polyurethane.

Conclusion

In conclusion, there are several existing patents for ready-to-use formulations of nicardipine, including oral, injectable, topical, and transdermal formulations. These patents demonstrate the ongoing efforts of pharmaceutical companies to develop novel formulations and delivery systems for nicardipine. As the patent landscape continues to evolve, it is likely that new formulations and delivery systems will be developed to improve the efficacy and safety of nicardipine.

Key Takeaways

* Nicardipine has been formulated for oral, injectable, topical, and transdermal use.
* Several patents have been granted for nicardipine formulations, including patents held by Pfizer Inc., Merck Sharp & Dohme Corp., Novartis AG, and Johnson & Johnson.
* Novel formulations and delivery systems for nicardipine are being developed to improve its efficacy and safety.

FAQs

1. What is nicardipine used to treat?
Nicardipine is used to treat various cardiovascular conditions, including hypertension, angina pectoris, and vasospastic angina.
2. What are the different formulations of nicardipine?
Nicardipine has been formulated for oral, injectable, topical, and transdermal use.
3. What are the benefits of novel formulations and delivery systems for nicardipine?
Novel formulations and delivery systems for nicardipine can improve its efficacy and safety, making it a more effective treatment option for patients.
4. Who holds the patents for nicardipine formulations?
Several pharmaceutical companies, including Pfizer Inc., Merck Sharp & Dohme Corp., Novartis AG, and Johnson & Johnson, hold patents for nicardipine formulations.
5. What is the patent landscape for nicardipine?
According to DrugPatentWatch.com, there are over 100 patents related to nicardipine, with many of them focusing on novel formulations and delivery systems.

Cited Sources

1. DrugPatentWatch.com. (n.d.). Nicardipine Patents. Retrieved from <https://www.drugpatentwatch.com/patents/nicardipine>
2. USPTO. (2002). US Patent 6,441,634. Retrieved from <https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=%2246441634%22.PN.&OS=PN/6441634&RS=PN/6441634>
3. USPTO. (2009). US Patent 7,851,017. Retrieved from <https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=%227851017%22.PN.&OS=PN/7851017&RS=PN/7851017>
4. USPTO. (2012). US Patent 8,263,933. Retrieved from <https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=%228263933%22.PN.&OS=PN/8263933&RS=PN/8263933>
5. USPTO. (2013). US Patent 8,623,933. Retrieved from <https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=%228623933%22.PN.&OS=PN/8623933&RS=PN/8623933>